As FDA steps up inspections of drug manufacturing plants in India and China, companies are holding mock inspections and bringing in outside consultants and lawyers to detect problems.
Douglas Farquhar, a director at Hyman, Phelps and McNamara who has helped numerous firms prepare for inspections, said the goal is to cure a problem before the inspection occurs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?